**6. Promotion of iPS reprograming by pharmacological or genetic inhibition of NFκB signaling.**

Various somatic cells have been successfully reprogramed into the ES-like pluripotent stem cells by a combination of factors or a single factor [108, 109]. During the reprogramming process, the classical NFκB signaling is inhibited [103, 106, 107]. Therefore, we speculate that NFκB inhibition might directly induce or promote the reprograming of iPS. Many specific inhibitors for NFκB signaling have been developed and some of them are applied to clinical trial [110]. In addition, fibroblasts or other somatic cells from transgenic mice deficient in NFκB signaling or clinical patients with mutation of NFκB signaling components can be easily accessible. It will be imperative to use NFκB inhibitors or genetic sources for easy and fast generation of iPS for drug discovery and cell transplantation studies.
